CrushSCI.com
96.2Average days
77Median days
31Fastest days
205Longest days
712025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

105 days

From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board

Authors
Tabea Fröhlich; Ulrich Lehmann; Tanja Reineke-Plaaß; Thomas Wirth; Sabrina Welland; Chen Du; Bernd Auber; Benjamin-Alexander Bollmann; Philipp Ivanyi; Tjoung-Won Park-Simon; Diana Steinmann; Christian Hartmann; Ariana de Oliviera Mekonnen; Anja Heutling; Andrea Schütte; Hans Heinrich Wedemeyer; Florian Heinrich Heidel; Susanne Isfort; Arndt Vogel; Anna SaborowskiShow moreShow less
Affiliations
1. Center for Personalized Medicine (Zentrum für Personalisierte Medizin, ZPM), Comprehensive Cancer Center (CCC) Hannover (Claudia von Schilling Center), Hannover Medical School, Hannover, Germany; 2. Department of Hematology, Hemostasis, Oncology and Cell Therapy, Hannover Medical School, Hannover, Germany; 3. PRACTIS Clinician Scientist Program, Dean’s Office for Academic Career Development, Hannover Medical School, Hannover, Germany; 4. Institute of Pathology, Hannover Medical School, Hannover, Germany; 5. Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany; 6. Institute of Human Genetics, Hannover Medical School, Hannover, Germany; 7. Department of Pneumology and Infectious Diseases, Hannover Medical School, Hannover, Germany; 8. Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; 9. Department of Radiation Oncology and Special Oncology, Hannover Medical School, Hannover, Germany; 10. Department of Neuropathology, Institute of Pathology, Hannover Medical School, Hannover, Germany; 11. Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; 12. Division of Gastroenterology and Hepatology, Toronto General Hospital, Medical Oncology, Princess Margaret Cancer Centre, Schwartz Reisman Liver Research Centre, Toronto, CanadaShow moreShow less
Source PDF DOI Publisher page
39 days

Real-World Treatment Patterns in Advanced Cutaneous Melanoma in the USA

Authors
Matthew S. Block; Ashley E. Stenzel; Rene Marcotte; Katrine L. WallaceShow moreShow less
Affiliations
1. Mayo Clinic, Comprehensive Cancer Center, Rochester, USA; 2. Replimune Inc, Woburn, USA; 3. RCM Consulting, Attleboro, USA; 4. University of Illinois Chicago, School of Public Health, Chicago, USAShow moreShow less
Source PDF DOI Publisher page
134 days

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies

Authors
Anikó Katalin Valikovics; Dániel Bacsó; Nadeen Samaien; Isabel Pinto Amorim das Virgens; Boglárka Szentes; Gergely Agócs; Mahmoud Obeidat; Tamás Széll; Boris Hadaschik; Péter Hegyi; Péter Nyirády; Tibor SzarvasShow moreShow less
Affiliations
1. Centre for Translational Medicine, Semmelweis University, Budapest, Hungary; 2. Department of Urology, Semmelweis University, Budapest, Hungary; 3. Department of Urology, University of Duisburg-Essen and German Cancer Consortium, Essen, Germany; 4. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary; 5. Institute of Pancreatic Diseases, Semmelweis University, Budapest, HungaryShow moreShow less
Source PDF DOI Publisher page
74 days

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma

Authors
Sai Sanikommu; Alejandro N. Santos; Bashar Dawoud; Khushi H. Shah; Sima Vazquez; Ashish H. Shah; Victor M. LuShow moreShow less
Affiliations
1. Department of Neurosurgery, Miller School of Medicine, University of Miami, Miami, USAShow moreShow less
Source PDF DOI Publisher page
70 days

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR -Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis

Authors
Yen-Hsiang Huang; Kuo-Hsuan Hsu; Jeng-Sen Tseng; Po-Hsin Lee; I-Hung Lin; Mu-Han Peng; Tsung-Ying YangShow moreShow less
Affiliations
1. Department of Chest Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 2. Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung, Taiwan; 3. School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; 4. Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan; 5. Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan; 6. Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 7. Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung, TaiwanShow moreShow less
Source PDF DOI Publisher page
76 days

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker

Authors
Hiroki Ishihara; Takayuki Nakayama; Hironori Fukuda; Nanaka Katsurayama; Yuki Nemoto; Shinsuke Mizoguchi; Hiroaki Shimmura; Yasunobu Hashimoto; Atsuko Seki; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; Yoji Nagashima; Toshio TakagiShow moreShow less
Affiliations
1. Department of Urology, Saiseikai Kawaguchi General Hospital, Kawaguchi, Japan; 2. Department of Urology, Tokyo Women’s Medical University, Tokyo, Japan; 3. Department of Urology, Tokyo Women’s Medical University Adachi Medical Center, Tokyo, Japan; 4. Department of Urology, Jyoban Hospital, Iwaki, Japan; 5. Department of Urology, Saiseikai Kazo Hospital, Kazo, JapanShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review62 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at [email protected]

Enter your email address so we can reply. Your details will remain private.